Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
12 September 2022 - 10:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: September 2022
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On
September 12, 2022, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”),
issued a press release announcing new preclinical data in a murine mesothelioma model showing a substantial and statistically significant
survival benefit when Allocetra™ is combined with the chemotherapeutic agent, cisplatin. A copy of such press release is furnished
as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd. |
|
(Registrant) |
|
|
|
By: |
/s/ Oren Hershkovitz |
|
Name: |
Oren Hershkovitz |
|
Title: |
Chief Executive Officer |
Date:
September 12, 2022
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024